Please login to the form below

Not currently logged in
Email:
Password:

antifungal

This page shows the latest antifungal news and features for those working in and with pharma, biotech and healthcare.

UK biotech bags €1.5m grant for new antibiotic class

UK biotech bags €1.5m grant for new antibiotic class

Last week, Scottish biotech NovaBiotics was awarded a £1.8m grant from Innovate UK to help support the development of Novamycin, a first-in-class antifungal compound with potential to combat

Latest news

More from news
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Basilea has granted an exclusive licence for isavuconazole (an iv and oral antifungal for invasive aspergillosis and mucomycosis) to Asahi Kasei in Japan.

  • Astellas: Ten years young Astellas: Ten years young

    class of OAB treatments to emerge in over 30 years, the antifungal Mycamine (micafungin) and the anti-infective Dificlir - the first new treatment in 50 years for clostridium difficile or c.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    109. Astellas / Vical. Licence and collaboration. Preclinical antifungal ASP2397. 100.

  • Pharma deals during October 2013 Pharma deals during October 2013

    This proved to be the case with Dow Pharmaceutical Sciences, which had undertaken development work for Anacor on the topical antifungal tavaborole for the treatment of onychomycosis under a 2004 master

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • AstraZeneca’s John Rex joins UK biotech F2G AstraZeneca’s John Rex joins UK biotech F2G

    new role Rex will be tasked with helping move F2G's first-in-class antifungal F901218 through phase II clinical trials. ... John Rex said: “I am delighted to have the opportunity to work more closely with F2G as we take the first orotomide antifungal

  • F2G appoints chief financial officer F2G appoints chief financial officer

    Schmid brings over two decades of financial management experience to the antifungal drug discovery and development company, with particular expertise in mergers and acquisitions, licensing and public and private market transactions.

  • Cidara Therapeutics makes senior appointments Cidara Therapeutics makes senior appointments

    Balkovec has helped bring more than a dozen development candidates into clinical development, including the first approved echinocandin antifungal drug Cancidas (caspofungin), which he is additionally co-inventor of.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics